STAT Plus: An FDA advisory panel is reviewing Amarin’s fish oil drug. Follow along for frequent updates

We’re monitoring Thursday’s meeting of the Food and Drug Administration advisory committee that is reviewing the heart-protective data on Vascepa, a drug derived from fish oil that is marketed by Amarin. Check back here often for analysis throughout the day.

Updates will be posted in reverse chronological order.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: An FDA advisory panel is reviewing Amarin’s fish oil drug. Follow along for frequent updates »